Life Sciences Real Estate Brokerage & Transactions

PharmaBioSource sources pharmaceutical and biotech manufacturing facilities for buyers seeking faster time-to-market than greenfield construction. Acquiring an existing GxP-ready facility can shave 18 to 36 months off a build and de-risk regulatory readiness from day one.

We conduct discreet, off-market searches for biologics, small-molecule API, sterile injectable, and oral solid-dose manufacturing facilities. Every pharma facility acquisition includes technical due diligence on utilities, cleanroom classification, equipment fit, and FDA inspection history, so buyers know what they own before closing.

When network consolidation, M&A integration, or portfolio rationalization puts a plant on the block, pharma facility divestiture requires targeted buyer outreach, not a public listing. Drawing on our tracked database of active acquirer mandates, we identify strategic acquirers, contract manufacturers, and investors whose stated criteria align with your facility profile.

Our marketing process safeguards confidentiality, ensures operational continuity, and presents the asset’s technical strengths to the right audience. Past divestments include small-molecule API plants, biologics suites, and sterile injectable fill-finish sites across North America, Europe, and Asia.

Pharma facility leasing lets growing biotechs and expanding manufacturers scale into GxP-ready space without the capital outlay of ownership. We represent tenants seeking lab space, fill-finish suites, or full manufacturing buildings, as well as landlords seeking qualified life sciences operators.

Lease structures in this segment are not standardized. Tenant improvement allowances, qualification timelines, regulatory contingencies, and exit terms all require sector-specific negotiation. We structure leases that protect both parties through commissioning, validation, and steady-state operations.

A sale-leaseback allows a pharma or biotech company to unlock capital tied up in an owned facility while operations continue uninterrupted. We structure transactions using life sciences real estate comparables rather than generic industrial data. Pharma-specific features sit outside standard industrial comp sets and are material to valuation.

We arrange introductions to life-sciences-focused real estate investors, negotiate lease terms that protect long-term operational control, and align the deal with the seller’s broader capital strategy. Common use cases include accelerating the funding pipeline, expanding R&D, and optimizing the post-merger balance sheet.

Pharma site selection decisions carry consequences for decades. Talent availability, supply chain proximity, state and local regulatory climate, utility capacity, and tax incentives all influence whether a facility achieves its full ROI.

We deliver location strategy analyses for greenfield manufacturing investments, expansion decisions, and consolidation plans. Each engagement scores candidate sites across cost, talent, regulatory, and logistics dimensions, benchmarks against comparable pharma site decisions, and connects clients with the economic development authorities and brokerage networks needed to execute.

Institutional investors and family offices target life sciences properties for stable, long-term tenants and durable demand, as the sector doesn’t track the broader industrial market. We source pharma and biotech assets that meet institutional underwriting standards, validate tenant credit, and assess facility-specific risks that generalist brokers often overlook.

We advise on individual asset acquisitions, portfolio strategy, and sale-leaseback origination. Our work spans GMP manufacturing facilities, biologics plants, API sites, and supporting lab and warehouse properties across primary and emerging life sciences clusters.

Pricing a pharma manufacturing facility is not a public-data exercise. Most transactions close privately, comps are hard to find, and a generalist appraisal often misvalues the building’s regulatory and equipment infrastructure.

We maintain a proprietary dataset of pharma facility transactions, lease comps, and sale-leaseback yields, compiled from our brokerage activity since 2002. Buyers, sellers, and investors use our benchmarking to validate offers, price divestments, and brief boards on realistic deal economics.

Facility transactions often include process equipment, which is sometimes worth more than the building. We connect clients with vetted pharmaceutical equipment dealers, refurbishers, and direct buyers for fillers, lyophilizers, bioreactors, isolators, and complete production lines.

Whether you are monetizing redundant assets after a consolidation or sourcing equipment for a new facility, our network compresses search time and surfaces options that public auctions miss. We also coordinate decommissioning, qualification, and shipping logistics as needed.